바이오미아퓨전(BMEA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.85 (+3.35%), 시가총액 $0.10B, 52주 최저~최고 $0.96 ~ $2.90.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatme
바이오미아퓨전의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
바이오미아퓨전의 현재 주가는 $1.85 (+3.35%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
바이오미아퓨전의 시가총액은 약 $0.10B입니다.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical pro